Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
Yazan F Madanat,1 Mitchell R Smith,2 Alexandru Almasan,3 Brian T Hill2 1Department of Internal Medicine, 2Department of Hematology and Medical Oncology, Taussig Cancer Institute, 3Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA Abstract: Chronic lymphoc...
Main Authors: | Madanat YF, Smith MR, Almasan A, Hill BT |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-03-01
|
Series: | Blood and Lymphatic Cancer: Targets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/idelalisib-therapy-of-indolent-b-cell-malignancies-chronic-lymphocytic-peer-reviewed-article-BLCTT |
Similar Items
-
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study
by: Beatrice Casadei, et al.
Published: (2022-01-01) -
Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia
by: Sara E. F. Kost, et al.
Published: (2019-10-01) -
Phosphatidylinositol 3-kinase-δ (PI3K-δ) is a potential therapeutic target in adult T-cell leukemia-lymphoma
by: Hiroo Katsuya, et al.
Published: (2018-07-01) -
Management of psoriasis-like rash associated with idelalisib monotherapy in a patient with refractory follicular lymphoma: a case report
by: Salma Machan, et al.
Published: (2020-02-01) -
Prognosis and new therapeutic approaches in chronic lymphocytic leukemia treatment
by: Otašević Vladimir, et al.
Published: (2019-01-01)